Blueprint Medicines (BPMC) and Insys Therapeutics (INSY) Critical Analysis
Blueprint Medicines (NASDAQ: BPMC) and Insys Therapeutics (NASDAQ:INSY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Earnings & Valuation
This table compares Blueprint Medicines and Insys Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Blueprint Medicines||$21.43 million||149.73||-$148.11 million||($3.92)||-18.67|
|Insys Therapeutics||$140.69 million||3.71||-$228.01 million||($0.49)||-14.43|
This table compares Blueprint Medicines and Insys Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
97.6% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 17.8% of Insys Therapeutics shares are owned by institutional investors. 3.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 65.4% of Insys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Blueprint Medicines and Insys Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Blueprint Medicines presently has a consensus price target of $87.11, suggesting a potential upside of 19.02%. Insys Therapeutics has a consensus price target of $9.67, suggesting a potential upside of 36.73%. Given Insys Therapeutics’ higher possible upside, analysts clearly believe Insys Therapeutics is more favorable than Blueprint Medicines.
Volatility & Risk
Blueprint Medicines has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Insys Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
Insys Therapeutics beats Blueprint Medicines on 8 of the 14 factors compared between the two stocks.
About Blueprint Medicines
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
About Insys Therapeutics
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.